The 2009 pandemic influenza has provided a unique opportunity to learn about influenza. Dose-sparing intradermal vaccination has been found to be effective in seasonal influenza [1] . However, this strategy has not been tested for the pandemic influenza. We therefore performed a prospective, randomized, open-label, singlecentre trial from January to March 2010, to compare the safety and immunogenicity between conventional full-dose intramuscular (IM) and low-dose (20%) intradermal (ID) immunizations of the monovalent 2009 H1N1 vaccine in chronically ill adults.
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Patients were randomized to receive a single low-dose (3µg hemagglutinin) ID vaccination or a single full-dose (15µg) IM vaccination. The vaccine used was Panenza® (Sanofi-Pasteur, France), a monovalent inactivated, non-adjuvanted vaccine formulated to contain 15µg of hemagglutinin of influenza A/California/07/2009 virus. Antibody titers were measured using hemagglutinationinhibition (HAI) and microneutralization (MN) assays according to standard methods [2] , at baseline, 21 and 42 days after vaccination. Avidity testing was performed by comparing the optical density after urea treatment in an ELISA assay [3] . Safety was assessed by the vaccinees completing the immediate adverse event checklist and a 7day diary.
A total of 37 subjects (ID:18 and IM:19) were enrolled. Two subjects in the IM group were lost to follow-up. Baseline demographics between the two groups were well matched. No deaths or serious adverse events were reported. Local symptom of post vaccination erythema was significantly more common in the ID group while other local and systemic symptoms were reported in similar frequency in both groups.
There was no significant difference in seroconversion and seroprotection rates by either assay (Table 1) (Table 1 ) showed no significant difference between the two groups, and between the day 21 and 42 samples. This is the first intradermal 2009 H1N1 vaccine evaluation. Data from this study suggested that immunogenicity of the monovalent H1N1 2009 vaccine was lower than previously published results for similar unadjuvanted 15µg split virus vaccines [4] .
This could be attributed to population selection (patients with chronic diseases or elderly) or high pre-immunization antibody response [5] . Adjuvants or booster dose should be considered to generate satisfactory immunogenicity [4] . The limitation of this study is the lack of appropriate sample size secondary to the widely report of an unrelated post vaccinee who developed Guillain-Barre syndrome, discouraging potential vaccinees who may benefit from this vaccine. In conclusion, dose sparing intradermal influenza vaccination is safe and effective and should be encouraged in elderly and immunosuppressed patients. This strategy should be incorporated in the pandemic preparedness plans globally.
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